A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Life Expectancy for Young People With HIV Is Nearly Normal
Failure to Awaken Dormant Cells Deals Blow to HIV Cure Research
Scientists Devise Method of Snipping HIV From Immune Cells
Media Cooks Up Claim That Soy Sauce Treats, Even Cures HIV
FDA Approves New Single-Tablet HIV Regimen, Triumeq
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

November 9, 2010

Contraceptive Patch No Better Than Pills for Interaction Problems With Protease Inhibitors

A patch that delivers hormonal contraceptives through the skin (transdermal) has just as much of a drug interaction problem with protease inhibitors (PIs) as oral versions of the birth control drugs, according to a study published in the December 1 issue of the Journal of Acquired Immune Deficiency Syndromes.

Many HIV medications can affect the blood levels of oral contraceptives, particularly Norvir (ritonavir)–boosted PIs. Most of the prescribing instructions for these antiretrovirals (ARVs) recommend an alternative form of birth control given that the PIs can significantly lower contraceptive blood levels.

Contraceptive drugs are also available in transdermal patches. Sometimes the chance of drug interactions can be reduced when the contraceptive is administered via skin applications instead of by mouth. However, no studies have been done to determine whether transdermal patches are any better than oral contraceptives when combined with PIs.

To test this, Mary Vogler, MD, from the Weill Cornell Medical College in New York City, and her colleagues conducted a study of 32 HIV-positive women, eight of whom were taking Kaletra (ritonavir-boosted lopinavir) and 24 of whom were not taking Kaletra. All of the women were given a single dose of oral contraceptives, followed 48 hours later by three weeks of transdermal patch contraceptives. Each patch lasted for seven days. Contractive blood levels, both ethinyl estradiol (EE) and norelgestromin (NGMN)—the combination of contraceptives in the pills and patches—were checked multiple times over the first 48 hours after the oral dose, and then at 12 to 48 hours, 48 to 72 hours and seven days after administrating each patch.

Vogler and her colleagues found that EE blood levels were about 50 percent lower in women taking Kaletra—both from the oral dose and the patch—than in women not taking Kaletra. Conversely, NGMN levels increased by more than 80 percent. Both types of oral contraceptives affected blood levels of the lopinavir and the ritonavir in the Kaletra by about 20 percent.

“An ongoing effort to investigate potential interactions between the next generations of contraceptive agents and both the current and next generations of [ARV therapy] is crucial to preserve the overall health of HIV-infected women, prevent pregnancy and inadvertent maternal to child transmission of HIV, and to allow family-planning when women’s health has been optimized in the presence of HIV,” the authors concluded.

Search: Oral contraceptive, transdermal patch, ethynil estradiol, norelgestromin, Mary Vogler, Kaletra, lopinavir, ritonavir, protease inhibitor, drug interaction


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    CuteBoyinQns
    Jackson Heights
    New York


    koffeeboss
    Tucson
    Arizona


    youngbloodlatino
    Columbia
    Maryland


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.